Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord-derived mesenchymal stem cells (3D)
- Development stage
- Preclinical
- Lead developer
- Yuanpin Cellular Biotechnology Group
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Umbilical cord-derived mesenchymal stem cells (3D) is a cell therapy candidate developed by Yuanpin Biotech for the treatment of Knee Osteoarthritis (KOA). The product consists of mesenchymal stem cells (MSCs) isolated from human umbilical cord tissue that are expanded using a three-dimensional (3D) culture technology. This 3D approach is designed to better replicate the natural physiological microenvironment of the cells compared to traditional two-dimensional (2D) monolayer cultures, which may enhance the cells' proliferative capacity, viability, and therapeutic potency. MSCs are known for their immunomodulatory and regenerative properties, functioning through the secretion of various bioactive molecules such as anti-inflammatory cytokines and growth factors. In the treatment of KOA, these cells are intended to reduce joint inflammation and promote the repair of damaged articular cartilage, typically administered via intra-articular injection.
- Other names
- 3D UC-MSC for Knee OsteoarthritisUC-MSC (3D) for KOAUmbilical Cord Mesenchymal Stem Cells (3D)
Beyond the preview
Go deeper on umbilical cord-derived mesenchymal stem cells (3D).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord-derived mesenchymal stem cells (3D).